secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2026-06-01T20:51:53+00:00
Accession:  0001790340-26-000059
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering reports 17.3-month median OS in Phase 2a pancreatic trial of atebimetinib
--------------------------------------------------------------------------------

- In 55-patient ITT population, mOS 17.3 months (cutoff Apr 24, 2026) vs 8.5 months standard of care.
- mPFS 8.3 months; ORR 36% (18/50), DCR 82% (41/50) in response-evaluable patients.
- 84% of evaluable patients maintained or gained weight; Grade ≥3 TEAEs: Anemia 16%, Neutropenia 18%.
- Expects first patient dosed in pivotal Phase 3 (MAPKeeper 301) mid-2026; topline data mid-2028.
- Plans Phase 1b/2 trial of atebimetinib+Libtayo in NSCLC starting H2 2026; data late 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034026000059/0001790340-26-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034026000059/imrx-20260601.htm
  HTML page:      https://secwatch.observer/filing/0001790340-26-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer